The Valley Desk

NCT03096080 · Interventional trial

A Safety, Pharmacokinetic, Single Ascending Dose Study of Tesevatinib in Pediatric Subjects With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Overall registry status Completed

Phase 1

Conditions Polycystic Kidney, Autosomal Recessive

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov